Cholesterol drug shows promise in halting skin pigment loss
NCT ID NCT02432534
Summary
This study tested if adding a high dose of the cholesterol-lowering drug atorvastatin to standard UVB light therapy could better control active vitiligo. It involved 28 adults whose vitiligo was actively spreading. For six months, one group received the drug plus light therapy, while the other received light therapy alone, to see which was more effective at stopping the spread and potentially repigmenting skin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nice
Nice, Alpes-Maritimes, 06001, France
-
National Skin center - 1 Mandalay Rd
Bedok, Singapore, 308205, Indonesia
Conditions
Explore the condition pages connected to this study.